Track Bristol-Myers Squibb Company — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Bristol-Myers Squibb Company BMYS.VI · Stock Open Bristol-Myers Squibb Company in new tab

52.98 EUR
P/E
14.00
EPS
3.89
Yield
4.26%
P/B
5.61
ROE
46.60
Beta
0.18
Loading chart...
Key Metrics
P/E14.00
EPS3.89
Book Value9.70
Price to Book5.61
Debt/Equity201.86
% Insiders0.097%
Growth
Revenue Growth0.06%
Earnings Growth1.53%
Dividend
Dividend Yield4.26%
Annual dividends2.25 EUR
Ex-Div. DateOct. 2, 2026
Payout55.29%
5y avg Yield3.83%

DCF valuation

Model fair value for Bristol-Myers Squibb Company (BMYS.VI)
Result
Sign in to run the valuation for BMYS.VI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Bristol-Myers Squibb Company Logo Bristol-Myers Squibb Company Analysis (BMYS.VI)

United States Health Care Official Website Stock

Is Bristol-Myers Squibb Company a good investment? Bristol-Myers Squibb Company (BMYS.VI) is currently trading at 52.98 EUR.

In terms of valuation, the stock trades at a P/E ratio of 14.00. This relatively low multiple may signal that Bristol-Myers Squibb Company is undervalued compared to historical market norms.

For income investors, Bristol-Myers Squibb Company pays a dividend yield of 4.26%. With a payout ratio of 55%, the dividend appears sustainable.

Investor FAQ

Does Bristol-Myers Squibb Company pay a dividend?

Yes, it pays an annual dividend of 2.25 EUR (4.26% yield).

What asset class is Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company is classified as a Stock.

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Trades
Dividend Yield
4.26%
5y avg 3.83%
Annual Dividends
2.25EUR
Next Ex. Div Date
Oct. 2, 2026
Payout Ratio
55.29%
Dividend History paid per year (EUR)
Historical Dividends
Year Total Dividends
▸2027
1.78 EUR
July 5, 2027 (estimated) 0.6014
April 2, 2027 (estimated) 0.5912
Jan. 4, 2027 (estimated) 0.5920
▸2026
2.24 EUR
Oct. 2, 2026 0.5598
July 2, 2026 0.5616
April 2, 2026 0.5616
Jan. 2, 2026 0.5616
▸2025
2.21 EUR
Oct. 3, 2025 0.5527
July 3, 2025 0.5527
April 4, 2025 0.5527
Jan. 3, 2025 0.5527
▸2024
2.14 EUR
Oct. 4, 2024 0.5349
July 5, 2024 0.5349
April 4, 2024 0.5349
Jan. 4, 2024 0.5349
▸2023
2.03 EUR
Oct. 5, 2023 0.5082
July 6, 2023 0.5082
April 6, 2023 0.5082
Jan. 5, 2023 0.5082
▸2022
1.93 EUR
Oct. 6, 2022 0.4814
June 30, 2022 0.4814
March 31, 2022 0.4814
Jan. 6, 2022 0.4814
▸2021
1.31 EUR
Sept. 30, 2021 0.4368
July 1, 2021 0.4368
March 31, 2021 0.4368
▸2020
2.04 EUR
Dec. 30, 2020 0.4368
Oct. 1, 2020 0.4012
July 2, 2020 0.4012
April 2, 2020 0.4012
Jan. 2, 2020 0.4012
▸2019
0.73 EUR
Oct. 3, 2019 0.3655
July 3, 2019 0.3655
Upcoming Dividends
Name Payment Date Status Amount
Bristol-Myers Squibb Company Oct 02, 2026 0.559755 EUR
Bristol-Myers Squibb Company Jul 02, 2026 0.561645 EUR
Bristol-Myers Squibb Company Apr 02, 2026 0.561645 EUR
Bristol-Myers Squibb Company Jan 02, 2026 0.561645 EUR
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion